By Cristina Roca 
 

Roche Holding AG said late Friday that its at-home Covid-19 test has been granted emergency-use authorization by the U.S. Food and Drug Administration and will be available across the country from January.

The Swiss pharmaceutical holding said the kit produces accurate results in as little as 20 minutes for all known variants of concern of the virus, including Omicron.

The test was prioritized by the FDA based on the ability of Roche and SD Biosensor Inc.--with which Roche has a global distribution agreement--to delivery large quantities and increase manufacturing to meet future demand. Roche has the capacity to produce tens of millions of tests a month, it said.

 

Write to Cristina Roca at cristina.roca@wsj.com

 

(END) Dow Jones Newswires

December 27, 2021 01:42 ET (06:42 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Roche (QX) Charts.